Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 172

1.

The prognostic impact of Consensus Molecular Subtypes (CMS) and its predictive effects for bevacizumab benefit in metastatic colorectal cancer: molecular analysis of the AGITG MAX clinical trial.

Mooi JK, Wirapati P, Asher R, Lee CK, Savas PS, Price TJ, Townsend A, Hardingham J, Buchanan D, Williams D, Tejpar S, Mariadason JM, Tebbutt NC.

Ann Oncol. 2018 Sep 21. doi: 10.1093/annonc/mdy410. [Epub ahead of print]

PMID:
30247524
2.

LBA-005VELOUR trial biomarkers update: Impact of RAS, BRAF, and sidedness on aflibercept activity.

Wirapati P, Pomella V, Vandenbosch B, Kerr P, Maiello E, Jeffery Grahame M, Razvan-Ovidiu D C, Karthaus M, John A B, Anca C M, Kiss I, Merino S, McKendrick Joseph J, Saridaki Z, Xavier Ja S, Tejpar S.

Ann Oncol. 2017 Jun 1;28(suppl_3). doi: 10.1093/annonc/mdx302.004. No abstract available.

PMID:
30052787
3.

Clinical and pharmacogenetic determinants of 5-fluorouracyl/leucovorin/irinotecan toxicity: Results of the PETACC-3 trial.

Tejpar S, Yan P, Piessevaux H, Dietrich D, Brauchli P, Klingbiel D, Fiocca R, Delorenzi M, Bosman F, Roth AD.

Eur J Cancer. 2018 Aug;99:66-77. doi: 10.1016/j.ejca.2018.05.009. Epub 2018 Jun 14.

PMID:
29909091
4.

Genetic editing of colonic organoids provides a molecularly distinct and orthotopic preclinical model of serrated carcinogenesis.

Lannagan TRM, Lee YK, Wang T, Roper J, Bettington ML, Fennell L, Vrbanac L, Jonavicius L, Somashekar R, Gieniec K, Yang M, Ng JQ, Suzuki N, Ichinose M, Wright JA, Kobayashi H, Putoczki TL, Hayakawa Y, Leedham SJ, Abud HE, Yilmaz ÖH, Marker J, Klebe S, Wirapati P, Mukherjee S, Tejpar S, Leggett BA, Whitehall VLJ, Worthley DL, Woods SL.

Gut. 2018 Apr 17. pii: gutjnl-2017-315920. doi: 10.1136/gutjnl-2017-315920. [Epub ahead of print]

PMID:
29666172
5.

Bcl-xL as a poor prognostic biomarker and predictor of response to adjuvant chemotherapy specifically in BRAF-mutant stage II and III colon cancer.

Dunne PD, Coleman HG, Bankhead P, Alderdice M, Gray RT, McQuaid S, Bingham V, Loughrey MB, James JA, McCorry AMB, Gilmore A, Holohan C, Klingbiel D, Tejpar S, Johnston PG, McArt DG, Di Nicolantonio F, Longley DB, Lawler M.

Oncotarget. 2018 Feb 13;9(17):13834-13847. doi: 10.18632/oncotarget.24481. eCollection 2018 Mar 2.

6.

Deregulation of ZIC Family Members in Oncogenesis.

Houtmeyers R, Souopgui J, Tejpar S.

Adv Exp Med Biol. 2018;1046:329-338. doi: 10.1007/978-981-10-7311-3_16. Review.

PMID:
29442329
7.

ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer.

Pietrantonio F, Di Nicolantonio F, Schrock AB, Lee J, Tejpar S, Sartore-Bianchi A, Hechtman JF, Christiansen J, Novara L, Tebbutt N, Fucà G, Antoniotti C, Kim ST, Murphy D, Berenato R, Morano F, Sun J, Min B, Stephens PJ, Chen M, Lazzari L, Miller VA, Shoemaker R, Amatu A, Milione M, Ross JS, Siena S, Bardelli A, Ali SM, Falcone A, de Braud F, Cremolini C.

J Natl Cancer Inst. 2017 Dec 1;109(12). doi: 10.1093/jnci/djx089.

PMID:
29370427
8.

A transatlantic perspective on the integration of immuno-oncology prognostic and predictive biomarkers in innovative clinical trial design.

Morfouace M, Hewitt SM, Salgado R, Hartmann K, Litiere S, Tejpar S, Golfinopoulos V, Lively T, Thurin M, Conley B, Lacombe D.

Semin Cancer Biol. 2018 Oct;52(Pt 2):158-165. doi: 10.1016/j.semcancer.2018.01.003. Epub 2018 Jan 5. Review.

PMID:
29307568
9.

Steps forward for cancer precision medicine.

Salgado R, Moore H, Martens JWM, Lively T, Malik S, McDermott U, Michiels S, Moscow JA, Tejpar S, McKee T, Lacombe D; IBCD-Faculty.

Nat Rev Drug Discov. 2018 Jan;17(1):1-2. doi: 10.1038/nrd.2017.218. Epub 2017 Nov 24.

PMID:
29170471
10.

Societal challenges of precision medicine: Bringing order to chaos.

Salgado R, Moore H, Martens JWM, Lively T, Malik S, McDermott U, Michiels S, Moscow JA, Tejpar S, McKee T, Lacombe D; IBCD-Faculty.

Eur J Cancer. 2017 Oct;84:325-334. doi: 10.1016/j.ejca.2017.07.028. Epub 2017 Sep 4.

PMID:
28865260
11.

Understanding the role of primary tumour localisation in colorectal cancer treatment and outcomes.

Stintzing S, Tejpar S, Gibbs P, Thiebach L, Lenz HJ.

Eur J Cancer. 2017 Oct;84:69-80. doi: 10.1016/j.ejca.2017.07.016. Epub 2017 Aug 5. Review.

12.

Prediction of overall survival in stage II and III colon cancer beyond TNM system: a retrospective, pooled biomarker study.

Dienstmann R, Mason MJ, Sinicrope FA, Phipps AI, Tejpar S, Nesbakken A, Danielsen SA, Sveen A, Buchanan DD, Clendenning M, Rosty C, Bot B, Alberts SR, Milburn Jessup J, Lothe RA, Delorenzi M, Newcomb PA, Sargent D, Guinney J.

Ann Oncol. 2017 May 1;28(5):1023-1031. doi: 10.1093/annonc/mdx052.

13.

Somatic POLE proofreading domain mutation, immune response, and prognosis in colorectal cancer: a retrospective, pooled biomarker study.

Domingo E, Freeman-Mills L, Rayner E, Glaire M, Briggs S, Vermeulen L, Fessler E, Medema JP, Boot A, Morreau H, van Wezel T, Liefers GJ, Lothe RA, Danielsen SA, Sveen A, Nesbakken A, Zlobec I, Lugli A, Koelzer VH, Berger MD, Castellví-Bel S, Muñoz J; Epicolon consortium, de Bruyn M, Nijman HW, Novelli M, Lawson K, Oukrif D, Frangou E, Dutton P, Tejpar S, Delorenzi M, Kerr R, Kerr D, Tomlinson I, Church DN.

Lancet Gastroenterol Hepatol. 2016 Nov;1(3):207-216. doi: 10.1016/S2468-1253(16)30014-0. Epub 2016 Jul 20.

PMID:
28404093
14.

Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer.

Dienstmann R, Vermeulen L, Guinney J, Kopetz S, Tejpar S, Tabernero J.

Nat Rev Cancer. 2017 Mar 23;17(4):268. doi: 10.1038/nrc.2017.24. No abstract available.

PMID:
28332502
15.

Comprehensive pharmacogenetic profiling of the epidermal growth factor receptor pathway for biomarkers of response to, and toxicity from, cetuximab.

Madi A, Fisher D, Maughan TS, Colley JP, Meade AM, Tejpar S, Van den Bosch B, Maynard J, Humphreys V, Wasan H, Adams RA, Idziaszczyk S, Harris R, Kaplan RS, Cheadle JP.

J Med Genet. 2017 Aug;54(8):567-571. doi: 10.1136/jmedgenet-2016-104317. Epub 2017 Mar 10.

PMID:
28283541
16.

Virtual chromoendoscopy (I-SCAN) detects more polyps in patients with Lynch syndrome: a randomized controlled crossover trial.

Bisschops R, Tejpar S, Willekens H, De Hertogh G, Van Cutsem E.

Endoscopy. 2017 Apr;49(4):342-350. doi: 10.1055/s-0042-121005. Epub 2017 Jan 20.

PMID:
28107763
17.

Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer.

Dienstmann R, Vermeulen L, Guinney J, Kopetz S, Tejpar S, Tabernero J.

Nat Rev Cancer. 2017 Feb;17(2):79-92. doi: 10.1038/nrc.2016.126. Epub 2017 Jan 4. Review. Erratum in: Nat Rev Cancer. 2017 Mar 23;17 (4):268.

PMID:
28050011
18.

Feedback activation of HER3 attenuates response to EGFR inhibitors in colon cancer cells.

Bosch-Vilaró A, Jacobs B, Pomella V, Abbasi Asbagh L, Kirkland R, Michel J, Singh S, Liu X, Kim P, Weitsman G, Barber PR, Vojnovic B, Ng T, Tejpar S.

Oncotarget. 2017 Jan 17;8(3):4277-4288. doi: 10.18632/oncotarget.13834.

19.

Expression profiling of budding cells in colorectal cancer reveals an EMT-like phenotype and molecular subtype switching.

De Smedt L, Palmans S, Andel D, Govaere O, Boeckx B, Smeets D, Galle E, Wouters J, Barras D, Suffiotti M, Dekervel J, Tousseyn T, De Hertogh G, Prenen H, Tejpar S, Lambrechts D, Sagaert X.

Br J Cancer. 2017 Jan 3;116(1):58-65. doi: 10.1038/bjc.2016.382. Epub 2016 Nov 24.

20.

Prognostic and Predictive Relevance of Primary Tumor Location in Patients With RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses of the CRYSTAL and FIRE-3 Trials.

Tejpar S, Stintzing S, Ciardiello F, Tabernero J, Van Cutsem E, Beier F, Esser R, Lenz HJ, Heinemann V.

JAMA Oncol. 2016 Oct 10. doi: 10.1001/jamaoncol.2016.3797. [Epub ahead of print]

PMID:
27722750
21.

Zic2 mutation causes holoprosencephaly via disruption of NODAL signalling.

Houtmeyers R, Tchouate Gainkam O, Glanville-Jones HA, Van den Bosch B, Chappell A, Barratt KS, Souopgui J, Tejpar S, Arkell RM.

Hum Mol Genet. 2016 Sep 15;25(18):3946-3959. doi: 10.1093/hmg/ddw235. Epub 2016 Jul 27.

PMID:
27466203
22.

ESMO consensus guidelines for the management of patients with metastatic colorectal cancer.

Van Cutsem E, Cervantes A, Adam R, Sobrero A, Van Krieken JH, Aderka D, Aranda Aguilar E, Bardelli A, Benson A, Bodoky G, Ciardiello F, D'Hoore A, Diaz-Rubio E, Douillard JY, Ducreux M, Falcone A, Grothey A, Gruenberger T, Haustermans K, Heinemann V, Hoff P, Köhne CH, Labianca R, Laurent-Puig P, Ma B, Maughan T, Muro K, Normanno N, Österlund P, Oyen WJ, Papamichael D, Pentheroudakis G, Pfeiffer P, Price TJ, Punt C, Ricke J, Roth A, Salazar R, Scheithauer W, Schmoll HJ, Tabernero J, Taïeb J, Tejpar S, Wasan H, Yoshino T, Zaanan A, Arnold D.

Ann Oncol. 2016 Aug;27(8):1386-422. doi: 10.1093/annonc/mdw235. Epub 2016 Jul 5.

PMID:
27380959
23.

BRAF V600E Mutant Colorectal Cancer Subtypes Based on Gene Expression.

Barras D, Missiaglia E, Wirapati P, Sieber OM, Jorissen RN, Love C, Molloy PL, Jones IT, McLaughlin S, Gibbs P, Guinney J, Simon IM, Roth AD, Bosman FT, Tejpar S, Delorenzi M.

Clin Cancer Res. 2017 Jan 1;23(1):104-115. doi: 10.1158/1078-0432.CCR-16-0140. Epub 2016 Jun 27.

24.

ICECREAM: randomised phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic colorectal cancer with either KRAS, NRAS, BRAF and PI3KCA wild type, or G13D mutated tumours.

Segelov E, Waring P, Desai J, Wilson K, Gebski V, Thavaneswaran S, Elez E, Underhill C, Pavlakis N, Chantrill L, Nott L, Jefford M, Khasraw M, Day F, Wasan H, Ciardiello F, Karapetis C, Joubert W, van Hazel G, Haydon A, Price T, Tejpar S, Tebbutt N, Shapiro J.

BMC Cancer. 2016 May 31;16:339. doi: 10.1186/s12885-016-2389-8.

25.

Cell Line Derived 5-FU and Irinotecan Drug-Sensitivity Profiles Evaluated in Adjuvant Colon Cancer Trial Data.

Buhl IK, Gerster S, Delorenzi M, Jensen T, Jensen PB, Bosman F, Tejpar S, Roth A, Brunner N, Hansen A, Knudsen S.

PLoS One. 2016 May 12;11(5):e0155123. doi: 10.1371/journal.pone.0155123. eCollection 2016.

26.

A Vulnerability of a Subset of Colon Cancers with Potential Clinical Utility.

Vecchione L, Gambino V, Raaijmakers J, Schlicker A, Fumagalli A, Russo M, Villanueva A, Beerling E, Bartolini A, Mollevi DG, El-Murr N, Chiron M, Calvet L, Nicolazzi C, Combeau C, Henry C, Simon IM, Tian S, in 't Veld S, D'ario G, Mainardi S, Beijersbergen RL, Lieftink C, Linn S, Rumpf-Kienzl C, Delorenzi M, Wessels L, Salazar R, Di Nicolantonio F, Bardelli A, van Rheenen J, Medema RH, Tejpar S, Bernards R.

Cell. 2016 Apr 7;165(2):317-30. doi: 10.1016/j.cell.2016.02.059.

27.

Awareness, Understanding, and Adoption of Precision Medicine to Deliver Personalized Treatment for Patients With Cancer: A Multinational Survey Comparison of Physicians and Patients.

Ciardiello F, Adams R, Tabernero J, Seufferlein T, Taieb J, Moiseyenko V, Ma B, Lopez G, Vansteenkiste JF, Esser R, Tejpar S.

Oncologist. 2016 Mar;21(3):292-300. doi: 10.1634/theoncologist.2015-0279. Epub 2016 Feb 17.

28.

Combined Epiregulin and Amphiregulin Expression Levels as a Predictive Biomarker for Panitumumab Therapy Benefit or Lack of Benefit in Patients With RAS Wild-Type Advanced Colorectal Cancer.

Seligmann JF, Elliott F, Richman SD, Jacobs B, Hemmings G, Brown S, Barrett JH, Tejpar S, Quirke P, Seymour MT.

JAMA Oncol. 2016 Feb 11. doi: 10.1001/jamaoncol.2015.6065. [Epub ahead of print]

PMID:
26867820
29.

Reduced Expression of SMAD4 Is Associated with Poor Survival in Colon Cancer.

Yan P, Klingbiel D, Saridaki Z, Ceppa P, Curto M, McKee TA, Roth A, Tejpar S, Delorenzi M, Bosman FT, Fiocca R.

Clin Cancer Res. 2016 Jun 15;22(12):3037-47. doi: 10.1158/1078-0432.CCR-15-0939. Epub 2016 Feb 9.

30.

DPYD Genotyping to Predict Adverse Events Following Treatment With Flourouracil-Based Adjuvant Chemotherapy in Patients With Stage III Colon Cancer: A Secondary Analysis of the PETACC-8 Randomized Clinical Trial.

Boige V, Vincent M, Alexandre P, Tejpar S, Landolfi S, Le Malicot K, Greil R, Cuyle PJ, Yilmaz M, Faroux R, Matzdorff A, Salazar R, Lepage C, Taieb J, Laurent-Puig P.

JAMA Oncol. 2016 Jan 21. doi: 10.1001/jamaoncol.2015.5392. [Epub ahead of print]

PMID:
26794347
31.

Microsatellite Instability and BRAF and KRAS Mutations in Stage III Colon Cancer: Requirements for Accurate Prognosis Assessment.

Klingbiel D, Tejpar S.

JAMA Oncol. 2016 Jan 14. doi: 10.1001/jamaoncol.2015.5226. [Epub ahead of print] No abstract available.

PMID:
26768497
32.

Charting the Course for a New Cancer Clinical Research Culture.

Tejpar S, Salgado R; Working Groups ‘Biomarker'' and ‘Clinical Trial Framework'' of the European Alliance for Personalised Medicine (EAPM).

Public Health Genomics. 2015;18(6):381-5. doi: 10.1159/000441558. Epub 2015 Nov 20.

PMID:
26584428
33.

DNA Topoisomerase I Gene Copy Number and mRNA Expression Assessed as Predictive Biomarkers for Adjuvant Irinotecan in Stage II/III Colon Cancer.

Nygård SB, Vainer B, Nielsen SL, Bosman F, Tejpar S, Roth A, Delorenzi M, Brünner N, Budinska E.

Clin Cancer Res. 2016 Apr 1;22(7):1621-31. doi: 10.1158/1078-0432.CCR-15-0561. Epub 2015 Nov 5.

34.

Prostatic biopsy-related rectal bleeding refractory to medical and endoscopic therapy definitively managed by catheter-directed embolotherapy: a case report.

De Beule T, Carels K, Tejpar S, Van Cleynenbreugel B, Oyen R, Maleux G.

J Med Case Rep. 2015 Oct 29;9:242. doi: 10.1186/s13256-015-0727-0.

35.

Expression of FOXP1 and Colorectal Cancer Prognosis.

De Smedt L, Palmans S, Govaere O, Moisse M, Boeckx B, De Hertogh G, Prenen H, Van Cutsem E, Tejpar S, Tousseyn T, Sagaert X.

Lab Med. 2015 Fall;46(4):299-311. doi: 10.1309/LM7IHV2NJI1PHMXC.

PMID:
26489674
36.

The consensus molecular subtypes of colorectal cancer.

Guinney J, Dienstmann R, Wang X, de Reyniès A, Schlicker A, Soneson C, Marisa L, Roepman P, Nyamundanda G, Angelino P, Bot BM, Morris JS, Simon IM, Gerster S, Fessler E, De Sousa E Melo F, Missiaglia E, Ramay H, Barras D, Homicsko K, Maru D, Manyam GC, Broom B, Boige V, Perez-Villamil B, Laderas T, Salazar R, Gray JW, Hanahan D, Tabernero J, Bernards R, Friend SH, Laurent-Puig P, Medema JP, Sadanandam A, Wessels L, Delorenzi M, Kopetz S, Vermeulen L, Tejpar S.

Nat Med. 2015 Nov;21(11):1350-6. doi: 10.1038/nm.3967. Epub 2015 Oct 12.

37.

Managing synchronous liver metastases from colorectal cancer: a multidisciplinary international consensus.

Adam R, de Gramont A, Figueras J, Kokudo N, Kunstlinger F, Loyer E, Poston G, Rougier P, Rubbia-Brandt L, Sobrero A, Teh C, Tejpar S, Van Cutsem E, Vauthey JN, Påhlman L; of the EGOSLIM (Expert Group on OncoSurgery management of LIver Metastases) group.

Cancer Treat Rev. 2015 Nov;41(9):729-41. doi: 10.1016/j.ctrv.2015.06.006. Epub 2015 Jun 30. Review.

38.

Clinical Validation of Targeted Next Generation Sequencing for Colon and Lung Cancers.

D'Haene N, Le Mercier M, De Nève N, Blanchard O, Delaunoy M, El Housni H, Dessars B, Heimann P, Remmelink M, Demetter P, Tejpar S, Salmon I.

PLoS One. 2015 Sep 14;10(9):e0138245. doi: 10.1371/journal.pone.0138245. eCollection 2015.

39.

KRAS, NRAS, BRAF mutation comparison of endoscopic and surgically removed primary CRC paired samples: is endoscopy biopsy material adequate for molecular evaluation?

Saridaki Z, Saegart X, De Vriendt V, Hatzidaki D, Palmans S, De Smedt L, De Hertogh G, Tejpar S.

Br J Cancer. 2015 Sep 15;113(6):914-20. doi: 10.1038/bjc.2015.307. Epub 2015 Sep 1.

40.

Single Nucleotide Polymorphism (rs4932178) in the P1 Promoter of FURIN Is Not Prognostic to Colon Cancer.

Declercq J, Jacobs B, Biesmans B, Roth A, Klingbiel D, Tejpar S, Creemers JW.

Biomed Res Int. 2015;2015:321276. doi: 10.1155/2015/321276. Epub 2015 Jun 7.

41.

Microsatellite instable vs stable colon carcinomas: analysis of tumour heterogeneity, inflammation and angiogenesis.

De Smedt L, Lemahieu J, Palmans S, Govaere O, Tousseyn T, Van Cutsem E, Prenen H, Tejpar S, Spaepen M, Matthijs G, Decaestecker C, Moles Lopez X, Demetter P, Salmon I, Sagaert X.

Br J Cancer. 2015 Jul 28;113(3):500-9. doi: 10.1038/bjc.2015.213. Epub 2015 Jun 11.

42.

Phase I study of FOLFIRI plus pimasertib as second-line treatment for KRAS-mutated metastatic colorectal cancer.

Macarulla T, Cervantes A, Tabernero J, Roselló S, Van Cutsem E, Tejpar S, Prenen H, Martinelli E, Troiani T, Laffranchi B, Jego V, von Richter O, Ciardiello F.

Br J Cancer. 2015 Jun 9;112(12):1874-81. doi: 10.1038/bjc.2015.144. Epub 2015 May 19.

43.

Integrating biomarkers in colorectal cancer trials in the West and China.

Tejpar S, Shen L, Wang X, Schilsky RL.

Nat Rev Clin Oncol. 2015 Sep;12(9):553-60. doi: 10.1038/nrclinonc.2015.88. Epub 2015 May 12. Review.

PMID:
25963094
44.

FOLFOX4 plus cetuximab treatment and RAS mutations in colorectal cancer.

Bokemeyer C, Köhne CH, Ciardiello F, Lenz HJ, Heinemann V, Klinkhardt U, Beier F, Duecker K, van Krieken JH, Tejpar S.

Eur J Cancer. 2015 Jul;51(10):1243-52. doi: 10.1016/j.ejca.2015.04.007. Epub 2015 Apr 30.

PMID:
25937522
45.

Establishment and characterization of models of chemotherapy resistance in colorectal cancer: Towards a predictive signature of chemoresistance.

Jensen NF, Stenvang J, Beck MK, Hanáková B, Belling KC, Do KN, Viuff B, Nygård SB, Gupta R, Rasmussen MH, Tarpgaard LS, Hansen TP, Budinská E, Pfeiffer P, Bosman F, Tejpar S, Roth A, Delorenzi M, Andersen CL, Rømer MU, Brünner N, Moreira JM.

Mol Oncol. 2015 Jun;9(6):1169-85. doi: 10.1016/j.molonc.2015.02.008. Epub 2015 Feb 24.

46.

Response.

Delorenzi M, Tejpar S, Roth AD, Bosman FT; all authors.

J Natl Cancer Inst. 2015 Mar 10;107(5). pii: djv056. doi: 10.1093/jnci/djv056. No abstract available.

PMID:
25758032
47.

IGF2 is an actionable target that identifies a distinct subpopulation of colorectal cancer patients with marginal response to anti-EGFR therapies.

Zanella ER, Galimi F, Sassi F, Migliardi G, Cottino F, Leto SM, Lupo B, Erriquez J, Isella C, Comoglio PM, Medico E, Tejpar S, Budinská E, Trusolino L, Bertotti A.

Sci Transl Med. 2015 Jan 28;7(272):272ra12. doi: 10.1126/scitranslmed.3010445.

48.

Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer.

Van Cutsem E, Lenz HJ, Köhne CH, Heinemann V, Tejpar S, Melezínek I, Beier F, Stroh C, Rougier P, van Krieken JH, Ciardiello F.

J Clin Oncol. 2015 Mar 1;33(7):692-700. doi: 10.1200/JCO.2014.59.4812. Epub 2015 Jan 20.

PMID:
25605843
49.

Optimising translational oncology in clinical practice: strategies to accelerate progress in drug development.

Stahel R, Bogaerts J, Ciardiello F, de Ruysscher D, Dubsky P, Ducreux M, Finn S, Laurent-Puig P, Peters S, Piccart M, Smit E, Sotiriou C, Tejpar S, Van Cutsem E, Tabernero J.

Cancer Treat Rev. 2015 Feb;41(2):129-35. doi: 10.1016/j.ctrv.2014.12.004. Epub 2014 Dec 16. Review.

50.

Personalized treatment is better than one treatment fits all in the management of patients with mCRC: a consensus statement.

Yalcin S, Trad D, Kader YA, Halawani H, Demir OG, Mall R, Meshcheryakov A, Nasr F, Nosworthy A, Osinsky D, Tumanova A, Turhal S, Tejpar S, Köhne CH.

Future Oncol. 2014 Dec;10(16):2643-57. doi: 10.2217/fon.14.203. Review.

Supplemental Content

Loading ...
Support Center